Back to Forecasting
BBIO Forecast Markets
BridgeBio Pharma
7
Active Markets
50%
Avg Probability
All Markets
7 markets
Will the U.S. tafamidis patent proceedings result in at least one Pfizer patent being invalidated by December 31, 2026?
38%
Likely No
94% agreement
Jan 31, 2027
IG: 0.80
Will BridgeBio's Attruby net product revenue exceed $175M in Q1 2026?
68%
Likely Yes
92% agreement
Aug 15, 2026
IG: 0.64
Will Attruby maintain or increase its ATTR-CM NBRx market share above 30% through H1 2026?
58%
Likely Yes
92% agreement
Oct 31, 2026
IG: 0.60
Will BridgeBio file an NDA for encaleret with the FDA by December 31, 2026?
58%
Likely Yes
92% agreement
Jan 31, 2027
IG: 0.56
Will BridgeBio's quarterly cash burn exceed $120M in either Q1 or Q2 2026?
45%
Likely No
94% agreement
Nov 15, 2026
IG: 0.48
Will BridgeBio's SG&A as a percentage of net product revenue decline below 70% by Q4 2026?
53%
Likely Yes
90% agreement
Mar 15, 2027
IG: 0.48
Will BridgeBio announce a share buyback program by December 31, 2026?
29%
Likely No
94% agreement
Jan 31, 2027
IG: 0.40
Resolution Timeline
Oct 31, 2026
Will Attruby maintain or increase its ATTR-CM NBRx market share above 30% through H1 2026?Prediction: 58%
Nov 15, 2026
Will BridgeBio's quarterly cash burn exceed $120M in either Q1 or Q2 2026?Prediction: 45%
Jan 31, 2027
Will BridgeBio file an NDA for encaleret with the FDA by December 31, 2026?Prediction: 58%
Mar 15, 2027
Will BridgeBio's SG&A as a percentage of net product revenue decline below 70% by Q4 2026?Prediction: 53%